Literature DB >> 2313562

Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro.

S Hosoi1, T Borsos, N Dunlop, P L Nara.   

Abstract

We studied inactivation of HIV-1 by fresh sera of animals. We found that while fresh sera of humans and chimpanzees (among others) did not have antiviral activity, fresh sera of several other mammals, especially those of rodents and felines, showed a dose-dependent viral-inactivating property against cell-free HIV-1; these sera were also capable of inactivating virus preadsorbed to cells, similar to neutralizing antibody. The activity was destroyed by heating to 56 degrees C, required Ca2+ but no antiviral antibody, and therefore apparently involves the classical complement pathway. The activity could not be ascribed to any single fraction of sera separated on a size exclusion HPLC column. Mouse serum (the only one tested) also inactivated HIV-2. The data are consistent with classical C-mediated pathway inactivation of HIV-1 and HIV-2 by animal sera and is the first report of any "complement-like" antilentiviral serum factor. Elucidation of this mechanism may aid in understanding the lack of activity of human serum against HIV-1 and may prove useful in combined interventive strategies against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313562

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  10 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain.

Authors:  Y Koyanagi; Y Tanaka; J Kira; M Ito; K Hioki; N Misawa; Y Kawano; K Yamasaki; R Tanaka; Y Suzuki; Y Ueyama; E Terada; T Tanaka; M Miyasaka; T Kobayashi; Y Kumazawa; N Yamamoto
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

4.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

5.  Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis.

Authors:  G T Spear; B L Sullivan; D M Takefman; A L Landay; T F Lint
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

6.  Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.

Authors:  S C Wu; J L Spouge; S R Conley; W P Tsai; M J Merges; P L Nara
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.

Authors:  Robert E Sealy; Bart G Jones; Sherri L Surman; Kristen Branum; Nanna M Howlett; Patricia M Flynn; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2015-11-06       Impact factor: 2.257

Review 8.  Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Authors:  Robert Sealy; Karen S Slobod; Patricia Flynn; Kristen Branum; Sherri Surman; Bart Jones; Pamela Freiden; Timothy Lockey; Nanna Howlett; Julia L Hurwitz
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

9.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design.

Authors:  Robert E Sealy; Barry Dayton; David Finkelstein; Julia L Hurwitz
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.